Manulife (Manufacturers Life Insurance)
BBIO icon

Manulife (Manufacturers Life Insurance)’s BridgeBio Pharma BBIO Stock Holding History

Manulife (Manufacturers Life Insurance)’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$146M Sell
1,955,733
-21,347
-1% -$1.5M 0.11% 176
2026
Q1 		$147M Buy
1,977,080
+1,765
+0.1% +$128K 0.13% 170
2025
Q4 		$151M Buy
1,975,315
+60,548
+3% +$3.97M 0.12% 165
2025
Q3 		$99.5M Buy
1,914,767
+23,189
+1% +$1.13M 0.08% 232
2025
Q2 		$81.7M Buy
1,891,578
+3,815
+0.2% +$139K 0.07% 246
2025
Q1 		$65.3M Buy
1,887,763
+1,969
+0.1% +$66.4K 0.06% 281
2024
Q4 		$51.7M Buy
1,885,794
+353,570
+23% +$9.14M 0.04% 350
2024
Q3 		$39M Sell
1,532,224
-2,748
-0.2% -$72.1K 0.03% 430
2024
Q2 		$38.9M Buy
1,534,972
+442,248
+40% +$12.1M 0.04% 407
2024
Q1 		$33.8M Buy
1,092,724
+348,592
+47% +$11.9M 0.03% 454
2023
Q4 		$30M Buy
744,132
+78,528
+12% +$2.36M 0.02% 496
2023
Q3 		$17.6M Buy
665,604
+419,813
+171% +$11.9M 0.01% 627
2023
Q2 		$4.23M Buy
245,791
+201,481
+455% +$3.03M ﹤0.01% 1160
2023
Q1 		$735K Buy
44,310
+408
+0.9% +$4.76K ﹤0.01% 1775
2022
Q4 		$335K Buy
43,902
+897
+2% +$8.59K ﹤0.01% 2239
2022
Q3 		$427K Sell
43,005
-793
-2% -$8.24K ﹤0.01% 2077
2022
Q2 		$398K Sell
43,798
-1,386
-3% -$11.6K ﹤0.01% 2199
2022
Q1 		$459K Sell
45,184
-9,480
-17% -$97.3K ﹤0.01% 2258
2021
Q4 		$912K Sell
54,664
-1,572
-3% -$66.5K ﹤0.01% 1892
2021
Q3 		$2.64M Sell
56,236
-5,200
-8% -$279K ﹤0.01% 1431
2021
Q2 		$3.75M Buy
61,436
+6,563
+12% +$375K ﹤0.01% 1396
2021
Q1 		$3.38M Buy
54,873
+10,270
+23% +$672K ﹤0.01% 1391
2020
Q4 		$3.17M Buy
44,603
+1,390
+3% +$67.1K ﹤0.01% 1388
2020
Q3 		$1.62M Sell
43,213
-1,154
-3% -$36.3K ﹤0.01% 1486
2020
Q2 		$1.45M Sell
44,367
-3,235
-7% -$98.5K ﹤0.01% 1489
2020
Q1 		$1.38M Buy
47,602
+31,594
+197% +$980K ﹤0.01% 1424
2019
Q4 		$561K Buy
16,008
+114
+0.7% +$3.16K ﹤0.01% 1985
2019
Q3 		$320K Buy
+15,894
New +$440K ﹤0.01% 2284

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Manulife (Manufacturers Life Insurance)'s BBIO Position: Q2 2026 in Review

Manulife (Manufacturers Life Insurance) reduced its BridgeBio Pharma (BBIO) stake by 1.1% in Q2 2026, selling an estimated $1.5M and leaving 1,955,733 shares worth $146M. The position accounts for 0.11% of the portfolio, ranked #176.

Manulife (Manufacturers Life Insurance) first reported a position in BBIO in Q3 2019 and has held it in 28 quarters since. The position peaked at $151M in Q4 2025. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Manulife (Manufacturers Life Insurance) held 1,955,733 shares of BridgeBio Pharma worth $146M as of Q2 2026.
  • Manulife (Manufacturers Life Insurance) sold 21,347 BridgeBio Pharma shares in Q2 2026, an estimated $1.5M.
  • BridgeBio Pharma made up 0.11% of Manulife (Manufacturers Life Insurance)'s portfolio in Q2 2026, its #176 holding.
  • Manulife (Manufacturers Life Insurance) first reported a position in BridgeBio Pharma in Q3 2019 and has held it in 28 quarters since.
  • Manulife (Manufacturers Life Insurance)'s BridgeBio Pharma position peaked at $151M in Q4 2025.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Manulife (Manufacturers Life Insurance)'s 13F filing for Q2 2026, filed 14 Aug 2026.